

Joel R Lexchin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/57761/publications.pdf>

Version: 2024-02-01

255
papers

8,781
citations

101543

36
h-index

56724

83
g-index

259
all docs

259
docs citations

259
times ranked

7395
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressants are not safe during pregnancy and in women of childbearing age. British Journal of Clinical Pharmacology, 2022, 88, 2447-2448.	2.4	2
2	Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality and Safety, 2022, 31, 179-190.	3.7	6
3	COVID-19 Vaccine Task Force and Conflicts of Interest. Healthcare Policy, 2022, 17, 20-27.	0.6	3
4	Pharmaceutical Company Payments to Healthcare Professionals and Healthcare Organizations in Canada: An Observational Study. Healthcare Policy, 2022, 17, 42-48.	0.6	1
5	National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study. BMJ Open, 2022, 12, e055287.	1.9	1
6	Hydroxyzine Initiation Following Drug Safety Advisories on Cardiac Arrhythmias in the UK and Canada: A Longitudinal Cohort Study. Drug Safety, 2022, , 1.	3.2	2
7	Use of priority and provisional approval pathways by the Australian Therapeutic Goods Administration in approving new medicines: a cross-sectional study. Australian Health Review, 2022, 46, 309-315.	1.1	1
8	Sponsorship of Canadian Professional Medical Societies by Drug, Medical Device and Medical Technology Companies: a Cross-sectional Study. Journal of General Internal Medicine, 2022, , .	2.6	1
9	After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada. International Journal of Health Services, 2022, 52, 341-346.	2.5	4
10	Sponsorship of Australian and New Zealand medical societies by healthcare companies: an observational study. JRSO Open, 2022, 13, 205427042211112.	0.5	0
11	Drug Promotion in India Since 2000: Problems Remain. International Journal of Health Services, 2021, 51, 392-403.	2.5	2
12	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical Pharmacology and Therapeutics, 2021, 109, 1424-1442.	4.7	12
13	Pharmaceuticals as a market for "lemons": Theory and practice. Social Science and Medicine, 2021, 268, 113368.	3.8	8
14	Time to Marketing of Generic Drugs After Patent Expiration in Canada. JAMA Network Open, 2021, 4, e211143.	5.9	3
15	A Ray of Sunshine: Transparency in Physician-Industry Relationships Is Not Enough. Journal of General Internal Medicine, 2021, 36, 3194-3198.	2.6	25
16	Achieving greater independence from commercial influence in research. BMJ, The, 2021, 372, n370.	6.0	12
17	Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis. International Journal of Risk and Safety in Medicine, 2021, 32, 331-341.	0.6	1
18	The potential benefits of a national vaccine registry for Canada. Cmaj, 2021, 193, E808-E808.	2.0	0

#	ARTICLE	IF	CITATIONS
19	Time to market for drugs approved in Canada between 2014 and 2018: an observational study. <i>BMJ Open</i> , 2021, 11, e047557.	1.9	4
20	Health Canada: optimizing transparency and its impact for patients. <i>Cmaj</i> , 2021, 193, E1503-E1503.	2.0	0
21	Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. <i>International Journal of Health Services</i> , 2021, 51, 5-13.	2.5	11
22	A sorry tale of unnecessary secrecy about medicine safety. <i>Internal Medicine Journal</i> , 2021, 51, 1765-1766.	0.8	0
23	A comparison of the Food and Drug Administration's and Health Canada's regulatory decisions about failed confirmatory trials for oncology drugs: an observational study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 93.	2.4	0
24	Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 475-479.	5.0	5
25	The costs of coronavirus vaccines and their pricing. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 502-504.	2.0	31
26	Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada. <i>International Journal of Health Policy and Management</i> , 2021, , .	0.9	0
27	Industry involvement in clinical practice guidelines. <i>Canadian Family Physician</i> , 2021, 67, 721.4-724.	0.4	1
28	Does an Orphan Drug Policy Make a Difference in Access? A Comparison of Canada and Australia. <i>International Journal of Health Services</i> , 2020, 50, 166-172.	2.5	4
29	Baclofen and Alcohol Use Disorders: Breakthrough or Great White Elephant?. <i>Alcohol and Alcoholism</i> , 2020, 55, 49-50.	1.6	6
30	Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature. <i>Health Policy</i> , 2020, 124, 231-238.	3.0	1
31	COVID-19: still much to learn. <i>Journal of the Royal Society of Medicine</i> , 2020, 113, 244-244.	2.0	0
32	Financial conflict of interest among clinical practice guideline-producing organisations. <i>British Journal of General Practice</i> , 2020, 70, 530-531.	1.4	1
33	A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States â€•2007 to 2016. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1054-1063.	1.9	9
34	Who assigns value in value-based insurance design?. <i>Cmaj</i> , 2020, 192, E15-E15.	2.0	0
35	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2020, 60, 840-851.	1.0	36
36	Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study. <i>BMJ Open</i> , 2020, 10, e035633.	1.9	8

#	ARTICLE	IF	CITATIONS
37	Quality of advertisements for prescription drugs in family practice medical journals published in Australia, Canada and the USA with different regulatory controls: a cross-sectional study. <i>BMJ Open</i> , 2020, 10, e034993.	1.9	9
38	Affordable Biologics for All. <i>JAMA Network Open</i> , 2020, 3, e204753.	5.9	8
39	The Rise and Fall of the Neurotic Housewife: Patient Sex in Psychotropic Drug Advertising to Physicians 1946–1990. <i>International Journal of Health Services</i> , 2020, 50, 292-298.	2.5	1
40	Restoring the Bacloville trial: efficacy and harms. <i>Addiction</i> , 2020, 115, 2184-2186.	3.3	6
41	Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. <i>BMJ</i> , The, 2020, 369, m1505.	6.0	49
42	Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. <i>Cmaj</i> , 2020, 192, E617-E625.	2.0	28
43	The “Nuts and Bolts” of Opioid Marketing: Promotional Messages to Family Doctors in Sacramento, Vancouver, Montreal, and Toulouse. <i>Journal of General Internal Medicine</i> , 2020, 35, 3730-3732.	2.6	1
44	Information and promotional strategies by pharmaceutical companies for clinicians. <i>The Cochrane Library</i> , 2020, , .	2.8	0
45	Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009. <i>Systematic Reviews</i> , 2020, 9, 77.	5.3	11
46	How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study. <i>PLoS ONE</i> , 2020, 15, e0240966.	2.5	4
47	Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	2
48	Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. <i>Journal of Law and the Biosciences</i> , 2020, 7, lsa083.	1.6	5
49	Health Canada’s Proposal to Accelerate New Drug Reviews. <i>Healthcare Policy</i> , 2020, 15, 26-34.	0.6	0
50	It’s Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada". <i>International Journal of Health Policy and Management</i> , 2020, 9, 528-530.	0.9	1
51	Engaging physicians to prescribe more cost-effectively: Blueprint for change. <i>Canadian Family Physician</i> , 2020, 66, 723-725.	0.4	0
52	Title is missing!. , 2020, 15, e0240966.		0
53	Title is missing!. , 2020, 15, e0240966.		0
54	Title is missing!. , 2020, 15, e0240966.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0240966.		0
56	Financial costs associated with monopolies on biologic medicines in Australia. Australian Health Review, 2019, 43, 36.	1.1	16
57	Medicines Information and the Regulation of the Promotion of Pharmaceuticals. Science and Engineering Ethics, 2019, 25, 1167-1192.	2.9	39
58	Declarations of interest by members of Health Canada's special advisory committees and panels: a descriptive study. CMAJ Open, 2019, 7, E334-E340.	2.4	6
59	Pharmaceutical Industry's "Initiated Postapproval Studies" Not Requested by the US FDA, Little Value, and Many Questions. JAMA Network Open, 2019, 2, e193392.	5.9	0
60	Innovation and off-label use, the French case and more. British Journal of Clinical Pharmacology, 2019, 85, 2446-2447.	2.4	3
61	The "pharmaceuticalisation" of life. BMJ: British Medical Journal, 2019, 365, l1972.	2.3	7
62	Canada finally opens up data on new drugs and devices. BMJ: British Medical Journal, 2019, 365, l1825.	2.3	7
63	Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom. JAMA Internal Medicine, 2019, 179, 982.	5.1	21
64	Secret safety warnings on medicines: A case study of information access requests. Pharmacoepidemiology and Drug Safety, 2019, 28, 551-555.	1.9	6
65	Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study. PLoS ONE, 2019, 14, e0212399.	2.5	15
66	An International Mapping of Medical Care in Nursing Homes. Health Services Insights, 2019, 12, 117863291882508.	1.3	7
67	Health Canada's Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis. International Journal of Health Services, 2019, 49, 294-305.	2.5	7
68	Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study. BMJ Open, 2019, 9, e030750.	1.9	6
69	The impact of post-market regulatory safety advisories on patients, prescribers, and the healthcare system. The Cochrane Library, 2019, , .	2.8	1
70	Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts. Globalization and Health, 2019, 15, 78.	4.9	33
71	National Partnership for Maternal Safety: Consensus Bundle on Venous Thromboembolism. Obstetrics and Gynecology, 2019, 134, 1115-1117.	2.4	1
72	Pathways to independence: towards producing and using trustworthy evidence. BMJ, The, 2019, 367, l6576.	6.0	79

#	ARTICLE	IF	CITATIONS
73	Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study. Healthcare Policy, 2019, 14, 10-18.	0.6	3
74	Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care Between Patients and Providers. Healthcare Policy, 2019, 14, 21-27.	0.6	4
75	Direct-to-consumer advertising of prescription medications: what the Canadian medical trainee needs to know. Canadian Medical Education Journal, 2019, 10, e113-e116.	0.4	0
76	Can direct-to-consumer advertising of prescription drugs be effectively regulated?. New Zealand Medical Journal, 2019, 132, 59-65.	0.5	1
77	Nursing Home Physicians Discuss Caring for Elderly Residents: An Exploratory Study. Canadian Journal on Aging, 2018, 37, 133-144.	1.1	7
78	Reconciling a “pleasant exchange” with evidence of information bias: A three-country study on pharmaceutical sales visits in primary care. Health Policy, 2018, 122, 250-255.	3.0	5
79	Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis. Journal of Pharmaceutical Policy and Practice, 2018, 11, 5.	2.4	24
80	The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries. Global Social Policy, 2018, 18, 7-27.	1.9	29
81	Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study. BMJ Open, 2018, 8, e020377.	1.9	8
82	Cost recovery by Health Canada and drug safety: a time-series analysis. CMAJ Open, 2018, 6, E471-E477.	2.4	0
83	Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario. International Journal of Health Services, 2018, 48, 702-715.	2.5	2
84	Ten Principles for More Conservative, Care-Full Diagnosis. Annals of Internal Medicine, 2018, 169, 643.	3.9	37
85	Canadian status of “drugs to avoid” in 2017: a descriptive analysis. CMAJ Open, 2018, 6, E430-E435.	2.4	3
86	Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence. Globalization and Health, 2018, 14, 86.	4.9	5
87	Health Canada’s use of expedited review pathways and therapeutic innovation, 1995–2016: cross-sectional analysis. BMJ Open, 2018, 8, e023605.	1.9	19
88	Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. BMJ: British Medical Journal, 2018, 361, k1039.	2.3	17
89	A call to mandate patient access to personal primary care medical records across Canada. Cmaj, 2018, 190, E869-E870.	2.0	8
90	Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Medicine, 2018, 44, 1603-1612.	8.2	97

#	ARTICLE	IF	CITATIONS
91	Combating corruption in the pharmaceutical arena. Indian Journal of Medical Ethics, 2018, 3, 234-239.	0.4	6
92	The term is misleading. Canadian Family Physician, 2018, 64, 792.	0.4	0
93	Industry sponsorship and research outcome. The Cochrane Library, 2017, 2017, MR000033.	2.8	772
94	Medicines Save, Medicines Kill. Drug Safety, 2017, 40, 457-459.	3.2	1
95	Myths and Realities About Why Prescription Drug Prices in the United States Are So High. Pharmaceutical Medicine, 2017, 31, 143-148.	1.9	0
96	Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychotherapy and Psychosomatics, 2017, 86, 168-170.	8.8	19
97	Drug prices: How do we get to a better place?. Cmaj, 2017, 189, E792-E793.	2.0	2
98	Continuing medical education and pharmaceutical industry involvement: An evaluation of policies adopted by Canadian professional medical associations. International Journal of Risk and Safety in Medicine, 2017, 29, 1-16.	0.6	7
99	The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis. CMAJ Open, 2017, 5, E724-E728.	2.4	16
100	Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST. Annals of Family Medicine, 2017, 15, 413-418.	1.9	24
101	Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study. Value in Health, 2017, 20, 1139-1142.	0.3	7
102	We need to mandate drug cost transparency on electronic medical records. Cmaj, 2017, 189, E1541-E1542.	2.0	9
103	Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis. BMJ Open, 2017, 7, e018372.	1.9	1
104	Priority reviews: innovation and safety. Cmaj, 2017, 189, E895-E895.	2.0	0
105	Publication of confirmatory studies required by Health Canada for drugs approved under a Notice of Compliance with conditions: a cohort study. CMAJ Open, 2017, 5, E295-E300.	2.4	3
106	The Pharmaceutical Industry and the Canadian Government: Folie À Deux. Healthcare Policy, 2017, 13, 10-16.	0.6	0
107	Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. British Journal of Clinical Pharmacology, 2017, 83, 2549-2556.	2.4	5
108	Skilled use of the media by vested interests to promote drugs and other health products. BMJ, The, 2016, 352, i1179.	6.0	0

#	ARTICLE	IF	CITATIONS
109	How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study. Healthcare Policy, 2016, 12, 65-75.	0.6	9
110	The Need to Systematically Evaluate Clinical Practice Guidelines. Journal of the American Board of Family Medicine, 2016, 29, 644-648.	1.5	22
111	Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase. BMC Health Services Research, 2016, 16, 383.	2.2	26
112	Observational Evidence of For-Profit Delivery and Inferior Nursing Home Care: When Is There Enough Evidence for Policy Change?. PLoS Medicine, 2016, 13, e1001995.	8.4	48
113	Off-label drug use and temporary recommendations for use: Rearranging the deckchairs on the Titanic?. Health Policy, 2016, 120, 890-891.	3.0	6
114	Hippocrates and Targin. Cmaj, 2016, 188, 1262.2-1262.	2.0	0
115	Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons. Pharmaceutical Medicine, 2016, 30, 277-289.	1.9	12
116	“Adaptive pathways” to drug authorisation: adapting to industry?. BMJ, The, 2016, 354, i4437.	6.0	38
117	The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia. International Journal of Health Services, 2016, 46, 597-613.	2.5	16
118	Off-Label Drug Use. American Journal of Medical Quality, 2016, 31, 285-285.	0.5	8
119	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. Healthcare Policy, 2016, 12, 18-36.	0.6	12
120	How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study. Healthcare Policy, 2016, 12, 65-75.	0.6	8
121	Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study. CMAJ Open, 2015, 3, E286-E291.	2.4	3
122	The effect of early in-hospital medication review on health outcomes: a systematic review. British Journal of Clinical Pharmacology, 2015, 80, 51-61.	2.4	44
123	Formulary status of drugs in Ontario after Health Canada has issued a serious safety warning: A cohort study. International Journal of Risk and Safety in Medicine, 2015, 27, 135-142.	0.6	1
124	Why do cancer drugs get such an easy ride?. BMJ, The, 2015, 350, h2068-h2068.	6.0	36
125	Health Canada's use of its priority review process for new drugs: a cohort study. BMJ Open, 2015, 5, e006816-e006816.	1.9	30
126	Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect. British Medical Bulletin, 2015, 116, ldv042.	6.9	7

#	ARTICLE	IF	CITATIONS
127	Why are there deadly drugs?. BMC Medicine, 2015, 13, 27.	5.5	5
128	Can reporting of adverse drug reactions create safer systems while improving health data?. Cmaj, 2015, 187, 789-790.	2.0	15
129	Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy. British Journal of Clinical Pharmacology, 2015, 79, 847-859.	2.4	35
130	The FDA's new clothes. BMJ, The, 2015, 351, h4897.	6.0	11
131	A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy, 2015, 119, 802-813.	3.0	51
132	Complete dissociation from the health care and pharmaceutical industry. Canadian Family Physician, 2015, 61, 668-9.	0.4	1
133	Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study. BMJ Open, 2014, 4, e004289.	1.9	5
134	Legislative regulation and ethical governance of medical research in different European Union countries. Journal of Medical Ethics, 2014, 40, 409-413.	1.8	31
135	A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation. International Journal of Risk and Safety in Medicine, 2014, 26, 213-225.	0.6	14
136	From <i>caveat emptor</i> to <i>caveat venditor</i>: time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice, 2014, 20, 809-812.	1.8	19
137	CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs. Globalization and Health, 2014, 10, 30.	4.9	24
138	Differences in the Volume of Pharmaceutical Advertisements between Print General Medical Journals. PLoS ONE, 2014, 9, e84790.	2.5	9
139	Quality and Quantity of Information in Summary Basis of Decision Documents Issued by Health Canada. PLoS ONE, 2014, 9, e92038.	2.5	10
140	How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Medicine, 2014, 8, e14-9.	1.5	12
141	Politics and its intersection with coverage with evidence development: a qualitative analysis from expert interviews. BMC Health Services Research, 2013, 13, 88.	2.2	18
142	Pharmaceutical Sales Representatives and Patient Safety. Journal of General Internal Medicine, 2013, 28, 1395-1395.	2.6	2
143	Canada and access to medicines in developing countries: intellectual property rights first. Globalization and Health, 2013, 9, 42.	4.9	4
144	What do Canadians think about physician-pharmaceutical industry interactions?. Health Policy, 2013, 112, 255-263.	3.0	15

#	ARTICLE	IF	CITATIONS
145	Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States. Journal of General Internal Medicine, 2013, 28, 1368-1375.	2.6	79
146	Who should fund CME?. Canadian Journal of Emergency Medicine, 2013, 15, 133.	1.1	0
147	Opioid abuse. Cmaj, 2013, 185, 418.2-418.	2.0	0
148	Surrogate Outcomes in Clinical Trials. JAMA Internal Medicine, 2013, 173, 611.	5.1	109
149	Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. Journal of Law, Medicine and Ethics, 2013, 41, 590-600.	0.9	112
150	Provincial Drug Plan Officials' Views of the Canadian Drug Safety System. Journal of Health Politics, Policy and Law, 2013, 38, 545-571.	1.9	6
151	Economics and industry do not mean ethical conduct in clinical trials. Journal of Pharmaceutical Policy and Practice, 2013, 6, 11.	2.4	3
152	Too Few, Too Weak: Conflict of Interest Policies at Canadian Medical Schools. PLoS ONE, 2013, 8, e68633.	2.5	38
153	Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship. Healthcare Policy, 2013, 9, 22-9.	0.6	3
154	New Drugs and Safety. Archives of Internal Medicine, 2012, 172, 1680.	3.8	61
155	Of money and trust in medical care redux. Mens Sana Monographs, 2012, 10, 143.	0.2	1
156	Harmony in Drug Regulation, but Who's Calling the Tune? An Examination of Regulatory Harmonization in Health Canada. International Journal of Health Services, 2012, 42, 119-136.	2.5	8
157	Industry sponsorship and research outcome. , 2012, 12, MR000033.		642
158	Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ, The, 2012, 345, e5155-e5155.	6.0	46
159	Sponsorship bias in clinical research. International Journal of Risk and Safety in Medicine, 2012, 24, 233-242.	0.6	95
160	International comparison of assessments of pharmaceutical innovation. Health Policy, 2012, 105, 221-225.	3.0	16
161	Models for financing the regulation of pharmaceutical promotion. Globalization and Health, 2012, 8, 24.	4.9	22
162	Pharmaceutical research and development: what do we get for all that money?. BMJ, The, 2012, 345, e4348-e4348.	6.0	168

#	ARTICLE	IF	CITATIONS
163	Those Who Have the Gold Make the Evidence: How the Pharmaceutical Industry Biases the Outcomes of Clinical Trials of Medications. <i>Science and Engineering Ethics</i> , 2012, 18, 247-261.	2.9	130
164	Pharmacovigilance in Europe and North America: Divergent approaches. <i>Social Science and Medicine</i> , 2012, 75, 165-170.	3.8	23
165	The cost of drug development: A systematic review. <i>Health Policy</i> , 2011, 100, 4-17.	3.0	379
166	The danger of imperfect regulation: OxyContin use in the United States and Canada. <i>International Journal of Risk and Safety in Medicine</i> , 2011, 23, 233-240.	0.6	28
167	Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?. <i>BMC Health Services Research</i> , 2011, 11, 64.	2.2	11
168	Beyond patents: The GAVI Alliance, AMCs and improving immunization coverage through public sector vaccine production in the global south. <i>Hum Vaccin</i> , 2011, 7, 291-292.	2.4	12
169	Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1008.	7.4	121
170	Ban Drug Advertisements. <i>Canadian Journal of Emergency Medicine</i> , 2011, 13, 297.	1.1	0
171	Coverage with Evidence Development for Pharmaceuticals: A Policy in Evolution?. <i>International Journal of Health Services</i> , 2011, 41, 337-354.	2.5	12
172	The association between a journal's source of revenue and the drug recommendations made in the articles it publishes. <i>Cmaj</i> , 2011, 183, 544-548.	2.0	16
173	Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: no. <i>Canadian Family Physician</i> , 2011, 57, 871, 873, 875, 877; discussion e276, e278.	0.4	0
174	Prohibiting or "managing" conflict of interest? A review of policies and procedures in three European drug regulation agencies. <i>Social Science and Medicine</i> , 2010, 70, 643-647.	3.8	41
175	Pharmaceutical innovation: Can we live forever? A commentary on Schnittker and Karandinos. <i>Social Science and Medicine</i> , 2010, 70, 972-973.	3.8	1
176	One step forward, one step sideways? Expanding research capacity for neglected diseases. <i>BMC International Health and Human Rights</i> , 2010, 10, 20.	2.5	15
177	Statistics in drug advertising: what they reveal is suggestive what they hide is vital. <i>International Journal of Clinical Practice</i> , 2010, 64, 1015-1018.	1.7	6
178	Drug safety and Health Canada. <i>International Journal of Risk and Safety in Medicine</i> , 2010, 22, 41-53.	0.6	4
179	Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. <i>PLoS Medicine</i> , 2010, 7, e1000352.	8.4	385
180	Canada's Access to Medicines Regime: Promise or Failure of Humanitarian Effort?. <i>Healthcare Policy</i> , 2010, 5, 40-8.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary. Healthcare Policy, 2010, 5, 26-36.	0.6	3
182	Institutional financial conflicts of interest policies at Canadian academic health science centres: a national survey. Open Medicine, 2010, 4, e134-8.	1.5	5
183	Le JCMU et les publicités pharmaceutiques : il est temps d'en finir. Canadian Journal of Emergency Medicine, 2009, 11, 380-384.	1.1	0
184	Pricing of multiple dosage prescription medications: An analysis of the Ontario Drug Benefit Formulary. Health Policy, 2009, 91, 142-147.	3.0	8
185	CJEM and pharmaceutical advertisements: it's time for an end. Canadian Journal of Emergency Medicine, 2009, 11, 375-379.	1.1	5
186	Indicators for measuring mental health: towards better surveillance. Healthcare Policy, 2009, 5, e177-86.	0.6	15
187	National Evaluation of Policies on Individual Financial Conflicts of Interest in Canadian Academic Health Science Centers. Journal of General Internal Medicine, 2008, 23, 1896-1903.	2.6	11
188	Drug Approval Times and User Fees. Pharmaceutical Medicine, 2008, 22, 1-11.	1.9	2
189	Clinical Trials in Canada: Whose Interests are Paramount?. International Journal of Health Services, 2008, 38, 525-542.	2.5	6
190	Physician awareness of diagnostic and nondrug therapeutic costs: A systematic review. International Journal of Technology Assessment in Health Care, 2008, 24, 158-165.	0.5	79
191	The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PLoS Medicine, 2008, 5, e1.	8.4	343
192	Poor Reporting of Scientific Leadership Information in Clinical Trial Registers. PLoS ONE, 2008, 3, e1610.	2.5	32
193	Medications for obesity. Canadian Family Physician, 2008, 54, 848-9; author reply 849-50.	0.4	0
194	Medicine reimbursement recommendations in Canada, Australia, and Scotland. American Journal of Managed Care, 2008, 14, 581-8.	1.1	25
195	Physician Awareness of Drug Cost: A Systematic Review. PLoS Medicine, 2007, 4, e283.	8.4	203
196	Educating Health Professionals about Drug and Device Promotion: Authors' Reply. PLoS Medicine, 2007, 4, e88.	8.4	0
197	Is Australia's National Medicines Policy Failing? the Case of Cox-2 Inhibitors. International Journal of Health Services, 2007, 37, 735-744.	2.5	1
198	'Linkage' pharmaceutical evergreening in Canada and Australia. Australia and New Zealand Health Policy, 2007, 4, 8.	2.2	22

#	ARTICLE	IF	CITATIONS
199	Regulating Drugs for Effectiveness and Safety: A Public Health Perspective. Medical Care, 2007, 45, 911.	2.4	1
200	Of Money And Trust In Biomedical Care. Mens Sana Monographs, 2007, 5, 7.	0.2	2
201	Different conclusions about memantine. Canadian Family Physician, 2007, 53, 403-4; author reply 404.	0.4	1
202	Notice of compliance with conditions: a policy in limbo. Healthcare Policy, 2007, 2, 114-22.	0.6	14
203	The secret things belong unto the Lord our God: secrecy in the pharmaceutical arena. Medicine and Law, 2007, 26, 417-30.	0.0	4
204	A comparison of new drug availability in Canada and the United States and potential therapeutic implications of differences. Health Policy, 2006, 79, 214-220.	3.0	6
205	Bigger and Better: How Pfizer Redefined Erectile Dysfunction. PLoS Medicine, 2006, 3, e132.	8.4	67
206	Educating Health Professionals about Drug and Device Promotion: Advocates' Recommendations. PLoS Medicine, 2006, 3, e451.	8.4	34
207	Adverse drug events: counting is not enough, action is needed. Medical Journal of Australia, 2006, 184, 315-316.	1.7	30
208	Commercial influence and the content of medical journals. BMJ: British Medical Journal, 2006, 332, 1444-1447.	2.3	77
209	Is there still a role for spontaneous reporting of adverse drug reactions?. Cmaj, 2006, 174, 191-192.	2.0	43
210	Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. Cmaj, 2006, 174, 1120-1121.	2.0	16
211	Relationship Between Pharmaceutical Company User Fees and Drug Approvals in Canada and Australia: A Hypothesis-Generating Study. Annals of Pharmacotherapy, 2006, 40, 2216-2222.	1.9	10
212	Are drugs too expensive in Canada? Yes. Canadian Family Physician, 2006, 52, 573-6, 578-81.	0.4	2
213	Rebuttal: are drugs too expensive in Canada?. Canadian Family Physician, 2006, 52, 841-2, 843-5.	0.4	1
214	Introduction of direct-to-consumer advertising of prescription drugs in Canada: An opinion survey on regulatory policy. Research in Social and Administrative Pharmacy, 2005, 1, 310-330.	3.0	9
215	Implications of Pharmaceutical Industry Funding on Clinical Research. Annals of Pharmacotherapy, 2005, 39, 194-197.	1.9	50
216	Intellectual Property Rights and the Canadian Pharmaceutical Marketplace: Where Do We Go from Here?. International Journal of Health Services, 2005, 35, 237-256.	2.5	19

#	ARTICLE	IF	CITATIONS
217	Drug withdrawals from the Canadian market for safety reasons, 1963-2004. Cmaj, 2005, 172, 765-767.	2.0	61
218	Foreign free riders and the high price of US medicines. BMJ: British Medical Journal, 2005, 331, 958-960.	2.3	59
219	Transparency in drug regulation: Mirage or oasis?. Cmaj, 2004, 171, 1363-1365.	2.0	16
220	Effects of Prescription Drug User Fees on Drug and Health Services Use and on Health Status in Vulnerable Populations: A Systematic Review of the Evidence. International Journal of Health Services, 2004, 34, 101-122.	2.5	160
221	The effect of generic competition on the price of brand-name drugs. Health Policy, 2004, 68, 47-54.	3.0	79
222	Stop the Merry-Go-Round. HealthcarePapers, 2004, 4, 29-34.	0.3	1
223	Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ: British Medical Journal, 2003, 326, 1167-1170.	2.3	1,733
224	The siren call of new drugs. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 513-515.	1.4	4
225	Safeguarding the Quality of Clinical Research. AMA Journal of Ethics, 2003, 5, 216.	0.7	1
226	Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No. Journal of Public Policy and Marketing, 2002, 21, 194-201.	3.4	106
227	The pharmaceutical industry as a medicines provider. Lancet, The, 2002, 360, 1590-1595.	13.7	133
228	Assessing the quality of drug detailing. Journal of Clinical Epidemiology, 2002, 55, 825-832.	5.0	19
229	New drugs with novel therapeutic characteristics. Have they been subject to randomized controlled trials?. Canadian Family Physician, 2002, 48, 1487-92.	0.4	3
230	Effects of restrictive formularies in the ambulatory care setting. American Journal of Managed Care, 2002, 8, 69-76.	1.1	17
231	To the editor:. Journal of Emergency Medicine, 2001, 20, 415.	0.7	1
232	Everyday experiences of implicit rationing: comparing the voices of nurses in California and British Columbia. Sociology of Health and Illness, 2001, 23, 633-653.	2.1	8
233	Double standards: double jeopardy. Pharmacoepidemiology and Drug Safety, 2000, 9, 289-290.	1.9	3
234	Letters to the Editor: Click, click: the internet and prescription drugs. Australian Prescriber, 2000, 23, 73-74.	1.0	3

#	ARTICLE	IF	CITATIONS
235	Esophageal detector devices and children. Canadian Journal of Emergency Medicine, 1999, 1, 162-163.	1.1	0
236	Hear No Secrets, See No Secrets, Speak No Secrets: Secrecy in the Canadian Drug Approval System. International Journal of Health Services, 1999, 29, 167-178.	2.5	2
237	Direct-To-Consumer Advertising. Disease Management and Health Outcomes, 1999, 5, 273-283.	0.4	11
238	Improving the Appropriateness of Physician Prescribing. International Journal of Health Services, 1998, 28, 253-267.	2.5	36
239	After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. Health Policy, 1997, 40, 69-80.	3.0	21
240	The Timeliness of New Drug Approvals in Canada: A Rejoinder. International Journal of Health Services, 1995, 25, 167-171.	2.5	1
241	Canadian Marketing Codes: How Well are They Controlling Pharmaceutical Promotion?. International Journal of Health Services, 1994, 24, 91-104.	2.5	9
242	Who Needs Faster Drug Approval Times in Canada: The Public or the Industry?. International Journal of Health Services, 1994, 24, 253-264.	2.5	12
243	Pharmaceuticals, Patents, and Politics: Canada and Bill C-22. International Journal of Health Services, 1993, 23, 147-160.	2.5	27
244	Pharmaceutical Promotion in the Third World. Journal of Drug Issues, 1992, 22, 417-453.	1.2	11
245	Prescribing and Drug Costs in the Province of Ontario. International Journal of Health Services, 1992, 22, 471-487.	2.5	13
246	Doctors and Detailers: Therapeutic Education or Pharmaceutical Promotion?. International Journal of Health Services, 1989, 19, 663-679.	2.5	78
247	The Medical Profession and the Pharmaceutical Industry: An Unhealthy Alliance. International Journal of Health Services, 1988, 18, 603-616.	2.5	11
248	PHARMACEUTICAL PROMOTION IN NEW ZEALAND. Community Health Studies, 1988, 12, 264-272.	0.0	3
249	Pharmaceutical Promotion in Canada: Convince Them or Confuse Them. International Journal of Health Services, 1987, 17, 77-89.	2.5	22
250	The Miracle of the Empty Beds: A History of Tuberculosis in Canada. Labour/Le Travail, 1980, 6, 233.	0.0	9
251	Pharmaceutical Research and Development: What Do We Get for All that Money?. SSRN Electronic Journal, 0, , .	0.4	5
252	The Trans Pacific Partnership Agreement and Pharmaceutical Regulation in Canada and Australia. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
253	Information and promotional strategies by pharmaceutical companies for clinicians. The Cochrane Library, 0, , .	2.8	0
254	The Pharmaceutical Industry in Contemporary Capitalism. Monthly Review, 0, , 37-50.	0.3	18
255	Evolution of Physician-Industry Relationships in Producing Knowledge of Drug Therapy - Comparison of the United States and Finland. SSRN Electronic Journal, 0, , .	0.4	0